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ABSTRACT
Objective: This study was designed to study the prevalence and antibiotic susceptibility patterns of Acinetobacter sp. as isolated from patients lodged 
in intensive care units (ICUs) of a tertiary care hospital, Ludhiana, Punjab, India.
Methods: The clinical samples were simultaneously streaked on Blood agar and MacConkey agar. The identification of the bacterial isolates was 
carried out with the aid of Gram stain, motility test and along with a combination of other commonly employed biochemical tests. The antimicrobial 
susceptibility testing (AST) of all the bacterial isolates was carried out on Muller-Hinton agar through Kirby-Bauer disc diffusion method.
Results: Acinetobacter sp. formed a fair allowance contributing at 42% among all ICU culture positive samples. The respiratory tract samples had a 
major share at 63.15% for all samples attributed to be positive for Acinetobacter sp. nosocomial etiology. The antibiotic sensitivity pattern portrayed 
that more than 95% of Acinetobacter sp. isolates were multiple drug resistant (MDR) whereas >50% Acinetobacter sp. showed extensive drug resistant 
(XDR). The last resort for such Acinetobacter sp. nosocomial infections is left to colistin and polymyxin B.
Conclusion: Acinetobacter sp. is a highly prevalent microorganism among ICU patients of Ludhiana, Punjab, India, while its potential to acquire 
resistance toward commonly used antibiotics represents it as a grave threat to the health-care industry, therefore signifying the need for its regular 
monitoring in the health-care setups.
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INTRODUCTION
Acinetobacter sp. is being credited as an omnipresent, Gram-negative 
coccobacilli, belonging to the family Moraxellaceae [1]. The bacteria 
are saprophytic, non-fastidious, rigidly aerobic, non-motile and 
known to exhibit pleomorphism. They form a part of the normal 
resident flora of the skin, respiratory, and intestinal tract [2]. 
Acinetobacters are oxidase negative organisms with an affirmation for 
catalase test. The genus includes 34 species of which 25 have valid 
names while the other 9 are named after their genomic group of which 
Acinetobacter baumannii is frequently ascribed in human infections 
[1]. The members of Acinetobacter sp. are extensively prevalent 
in soil, water, humans, and animals [3]. They have extraordinary 
ability to grow at a wide range of temperatures and pH, to survive 
on moist and dry surfaces, tolerate exposure to various commonly 
used disinfectants thereby allowing some Acinetobacter species (A. 
baumannii, A. iwoffii, and A. haemolyticus) to thrive well in hospital 
environment too [3]. The Acinetobacter sp. is found to be the second 
most common Gram-negative pathogen isolated from clinical samples 
after Pseudomonas aeruginosa [4]. The prevalence of A. baumannii 
is highly seen among debilitated or immunocompromised patients 
especially those who have experienced greater than 90 days of 
hospital stay [5]. A. baumannii is attributed to cause nosocomial or 
hospital-acquired infections (HAIs), particularly in patients those 
who have been lodged in intensive care units (ICUs) on account of 
having a breach in their immunity by one means or the other. The 
risk factors in ICUs include presence of indwelling urinary catheters, 
central venous lines, ventilator or other intubations, exposure to 
broad-spectrum antibiotics, immunosuppression in lieu of any 
underlying disease as diabetes mellitus, and HIV, peritoneal dialysis, 
neurosurgical interventions, or any other surgical procedures [6-9]. 
The most common HAIs caused by A. baumannii include bacteremia, 
genital and urinary tract infections (UTIs), iatrogenic or secondary 
meningitis, and infective endocarditis along with wound and burn 
infections [10]. The European ICU surveillance data (2009) showed 
that Acinetobacter sp. was credited at 11.9–21.8% times in ICU 
acquired infections [1]. The highlighting problem with Acinetobacter 
infections is its capability to acquire high-grade innate resistance 
against all commonly used antibiotics (multiple drug resistance 
[MDR]) with a stupendous overall mortality rate of 26–68% [11-13]. 
The MDR ability of Acinetobacter sp. can be explained on account of its 
ability to portray different mechanisms as synthesis of β-lactamases 
and other antibiotic modifying enzymes, overexpression of efflux 
pumps, loss of porin channels across the cellular membranes, target 
mutations along with mutations in ribosomes or lipopolysaccharide 
structure [14].
The lack of standard identification techniques makes identification of 
Acinetobacter sp. a cumbersome task. The studies done to depict the 
status and gravity of Acinetobacter infections all over the world shows 
a grim picture. With respect to the Indian subcontinent, the studies 
done in context with Acinetobacter sp. exhibits it as one of the most 
frequent and commonly isolated pathogens especially prevalent in ICUs 
of tertiary care hospitals which are otherwise considered as “Mecca 
of recovery.” The antibiotic susceptibility tests thoroughly decipher 
the MDR nature of the Acinetobacters along with their inborn ability 
to depict high-grade resistance even to the last resort antibiotics as 
carbapenems and colistin. Hence, this study was designed to have an 
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overview of the prevalence of Acinetobacter sp. in the ICU patients 
of a tertiary care hospital, Ludhiana, Punjab, India, along with their 
concurrent sensitivity/resistance patterns toward commonly used 
or last resort antibiotics, so as to timely design out effective infection 
control measures against the same.
METHODS
Chemicals
The basal media including Nutrient broth, Blood agar (BA) base, 
MacConkey agar, and Mueller Hinton agar (MHA) were procured from 
HiMedia, Mumbai. The others in the list included Crystal violet, Lugol’s 
iodine, acetone, ethanol, safranin, ethylenediaminetetracetic acid 
(EDTA), hydrogen peroxide, p-dimethylaminobenzaldehyde, Iso-amyl 
alcohol, concentrated hydrochloric acid, peptone, glucose, dipotassium 
hydrogen phosphate, methyl red (MR), potassium hydroxide, 
α-naphthol, Simmon’s Citrate agar, tetramethyl para phenylene diamine 
dihydrochloride, Urea agar base (Christensen), sulfanilic acid, acetic 
acid, α-naphthylamine, and distilled water.
Study population and sample collection
This study was undertaken during 2015, at a tertiary care hospital in 
Ludhiana, Punjab, India. A total of 298 clinical samples were collected 
which mainly fell under three broad groups or categories, namely Pus, 
Blood, and Urine. The pus category broadly included samples such as 
bronchoalveolar lavage (BAL), mini BAL, sputum, Cerebrospinal fluid, 
tips (Endotracheal tube tips, central lines, cava fix tips, and other 
catheter tips), superficial pyogenic infections or bland pus samples, 
swabs (throat, high vaginal, bedsore, and wound), body fluids (pleural, 
peritoneal, tracheal, and skin blister), and external ventricular drain 
and a biopsy specimen. The blood samples comprised of venous blood, 
peripheral blood, bone marrow aspirate, etc. The urine samples were a 
mix of bland urine samples along with a catheter tip. All samples were 
collected under aseptic conditions [15].
Culture and identification
All the samples including bland pus, respiratory tract samples, 
fluids, swabs and urine samples were surface streaked onto BA and 
MacConkey agar plates. The catheter or central line tips along with the 
biopsy specimen were directly inoculated in Nutrient broth for 24 h and 
later streaked on to the surface of BA and MacConkey agar plates. All 
the plates were incubated at 37°C for 24 h and later on observed for the 
visible bacterial growth. The blood samples and bone marrow aspirates 
were directly inoculated into the commercially prepared blood culture 
bottles (BD BACTEC) and incubated in an automated blood culture 
system (BACTEC) up to 7 days with periodic monitoring. The positive 
blood culture samples so obtained for bacterial growth were also later 
on seeded onto BA and MacConkey agar plates.
The bacterial isolates were identified based on a combination 
of phenotypic and biochemical characteristics including colony 
characteristics as inscribed on BA and MacConkey agar, Gram’s staining, 
motility test along with an array of other common biochemical tests as 
coagulase, catalase, indole, MR and Voges Proskauer, citrate, oxidase, 
urease, and nitrate reductase [16,17].
Antibiotic sensitivity test
Antibiotics used
All the bacterial cultures were screened for their sensitivity against 
a panel comprising commonly used first, second, and third line 
antibiotics in the format of standard discs as amikacin (AK, 30 
μg), ampicillin (AMP, 10 μg/disc), cefoperazone (CPZ, 75 μg/disc), 
cefoperazone/sulbactam (CFS, 75/30 μg/disc), cefotaxime (CTX, 30 
μg/disc), cefoxitin (CX, 30 μg/disc), ceftazidime (CAZ, 30 μg/disc), 
ceftriaxone (CTR, 30 μg/disc), chloramphenicol (C, 30 μg/disc), 
ciprofloxacin (CIP, 5 μg/disc), colistin (10 μg/disc), cotrimoxazole (COT, 
1.25/23.75 μg/disc), gentamycin (GEN, 10 μg/disc), imipenem (IPM, 10 
μg/disc), meropenem (MRP, 10 μg/disc), netromycin (NET, 30 μg/disc), 
ofloxacin (OF, 5 μg/disc), piperacillin/tazobactam (PIT, 100/10 μg/
disc), polymyxin B (PB, 300 units/disc), ticarcillin (TI, 75 μg/disc), and 
tobramycin (TOB, 10 μg/disc). All the antibiotic discs were obtained 
from HiMedia, Mumbai, and stored under standard conditions.
Susceptibility testing
The antimicrobial susceptibility of all bacterial isolates was tested 
through Kirby-Bauer disc diffusion susceptibility test method on 
MHA plates (HiMedia, Mumbai) as per the guidelines of Clinical and 
Laboratory Standards Institute (CLSI 2017) [18]. The isolates were 
inoculated in Nutrient broth (0.5 McFarland standards) and seeded 
onto the MHA plates using sterilized cotton swabs. The plates were 
left to dry for a few minutes. The antibiotic discs were placed onto the 
surface of agar plates using sterilized forceps. All the plates were then 
incubated at 37°C for 24 h so as to evaluate the antimicrobial activity by 
measuring the diameter of the zone of inhibition around the antibiotic 
discs and then interpreting them according to the CLSI guidelines.
RESULTS
Study population and sample collection
This study was basically a prospective observational study. All the 
clinical samples were collected from patients of different age and sex, 
who have been admitted to varied ICUs for more than 72 h. Of the 
aggregate of 298 clinical samples collected, the amount of samples 
sorted for the pus or pyogenic category came out to be at 142 while a 
total of 102 samples falling in the category of blood samples along with 
54 samples as identified for urine category were also simultaneously 
collected (Table 1).
Isolation of the pathogenic bacteria
Out of the total 298 clinical samples so collected, 69 (23.15%) 
samples came out to be positive in routine culture which is clearly 
depicted in Fig. 1. The various isolates were identified and sorted 
on the aforementioned criteria. Out of the total positive isolates, 
Table 1: Comparative distribution of various clinical samples as 
collected from varied ICUs
Sample group Sample type Sample number





Superficial pyogenic infections 6
Swabs 6
Body fluids 17





ICUs: Intensive care units
Fig. 1: Comparative assessment of total collected samples and 
culture positive samples
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highest share was recorded for Acinetobacter sp. (42.02%), followed 
by P. aeruginosa (15.94%), Klebsiella sp. (14.49%), Escherichia coli 
(13.04%), Staphylococcus aureus (4.34%), Enterococcus sp. (4.34%), 
and Enterobacter sp. (4.34%) and the least being attributed to 
Pneumococcus (1.44%). The comparative percentage distribution for 
various nosocomial ICU isolates is shown in Fig. 2.
Characterization and prevalence of Acinetobacter sp.
The microscopic examination for Gram staining represented 
Acinetobacter sp. to be short, Gram-negative, coccobacilli, arranged 
singly or in pairs. The isolates were identified as Acinetobacter sp. by 
the appearance of white to cream colored, smooth, circular colonies 
with an entire edge, as seen on BA and being non-fermenting with a 
bit of pinkish tinge as seen on MacConkey agar which can be primarily 
visualized in Fig. 3 [19]. On further incubation up to 48 h, the size of 
the colonies increased, and they became mucoid. The Acinetobacter sp. 
showed positivity for catalase test, whereas it came out to be negative 
for motility test, oxidase test, indole, MR, and urease test [19-21].
The highest pathogenic bacterial existence was asserted for 
Acinetobacter sp. being at a breathtaking stature of 42.02% among all 
the culture positive ICU isolates while Pneumococcus accounted for 
being the lowest at 1.44%. Of the total 29 Acinetobacter sp. positive 
samples, 23 were only containing Acinetobacter sp. whereas the 
remaining 6 samples, along with Acinetobacter sp. were also containing 
other pathogenic bacteria such as P. aeruginosa (5 samples) and E. 
coli (1 sample). The aggregate percentage for Gram-positive isolates 
came out to be at 10.14% whereas the percentage of all Gram-negative 
isolates stood by a whopping 89.85% thus, highlighting the prevalence 
of Gram-negative pathogens as the major nosocomial etiological agents 
in the ICUs of Ludhiana, Punjab, India.
Acinetobacter sp. and associated infections
The different types of infections attributed to Acinetobacter sp. 
as summarized in Table 2, showed that respiratory tract was the 
predominantly affected area (63.15%) in the otherwise vulnerable ICU 
patients and the least susceptible system was the hemopoietic system 
or the plethora of bloodstream (7.14%).
Antimicrobial susceptibility testing (AST) for Acinetobacter sp. 
isolates
A total of 29 Acinetobacter sp. isolates obtained in this study were 
subjected to AST using agar disc diffusion method. Based on the CLSI 
guidelines 2017, the effects shown by standard antibiotics against 
various Acinetobacter sp. isolates, were classified as sensitive (S), 
intermediate (I), and resistant (R). The results of antimicrobial 
sensitivity pattern of various Acinetobacter sp. ICU isolates against 
commonly used antibiotics can be thus visualized and easily interpreted 
in Table 3.
Ranking of antibiotic resistance for various Acinetobacter sp. 
isolates
The ranking of antibiotic resistance for various Acinetobacter sp. 
isolates toward commonly used antibiotics is summarized in Table 4. 
The results specified that all Acinetobacter sp. isolates in this study 
were mostly MDR, which represent a significant concern and threat.
A full cent percent (100%) resistant was encountered by antibiotics 
such as AMP, some second-generation cephalosporins as CPZ, CTX, 
CX, CTR, and a β -lactam antibiotic as TI, which paved the way for 
labeling these drugs as being the top-ranked drugs with respect to 
the pedestal of drug resistance. The ranking for antibiotic resistance 
showed a descending trend in context with drugs as CAZ (96.55%), 
a fluoroquinolone as CIP (96.55%), followed by COT (89.65%), PIT 
(89.65%), aminoglycosides as AK (86.20%) and GEN (86.20%), again to 
be followed by a fluoroquinolone as OF (82.75%), aminoglycosides as 
TOB (82.75%) and NET (79.31%), carbapenems as IPM (65.51%) and 
MRP (65.51%), C (62.06%), and CFS (55.17%), and least resistance was 
experienced by polymyxins as CL (3.44%) and PB (0%) thereby ranking 
them to be the most sensitive drugs and the only last living hope on the 
present drug horizon.
DISCUSSION
The ability of the bacterium to survive on inanimate surfaces for 
prolonged time periods extending from 3 days to 5 months, facilitates 
its spread in health-care settings thus, it can be easily detected on 
various common and routine use health care set up items as sinks, 
floors, cupboards, bed linens, mattresses, bed rails, curtains, hospital 
trolleys, and ventilation equipment such as respirators and AMBU bags 
[14].
The MDR isolates of Acinetobacter sp. are globally emerging as a 
serious opportunistic nosocomial threat particularly in the ICUs. The 
multidrug-resistant (MDR) Acinetobacter sp. is defined as the one which 
is resistant to all three classes of antimicrobial agents as - penicillins, 
cephalosporins, fluoroquinolones, and aminoglycosides. The extensive 
drug resistant (XDR) Acinetobacter sp. shall be the MDR isolates which 
are also resistant to carbapenems (IPM and MRP) [22].
Fig. 2: Percentage distribution for various nosocomial intensive 
care unit isolates
Table 2: Comparative distribution of various Acinetobacter sp. associated infections
Type of infection Total number of positive samples Number of samples positive for Acinetobacter sp. % Distribution
Respiratory infections 38 24 63.15
Bloodstream infections 14 1 7.14
Surgical site infections 7 1 14.28
Urinary tract infections 6 1 16.66
Superficial pyogenic infections 4 2 50
Fig. 3: Identification of Acinetobacter sp. (a) Growth on Blood agar 
(b) Growth on MacConkey agar (c) Gram staining
cba
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Table 3: Antibiotic sensitivity pattern of Acinetobacter sp. isolates against commonly used antibiotics
Antibiotic used Symbol Dose (μg/disc) N (%) Total
Sensitive (S) Intermediate (I) Resistant (R)
Amikacin AK 30 3 (10.34) 1 (3.44) 25 (86.20) 29
Ampicillin AMP 10 0 (0) 0 (0) 29 (100) 29
Cefoperazone CPZ 75 0 (0) 0 (0) 29 (100) 29
Cefoperazone/Sulbactam CFS 75/30 9 (31.03) 4 (13.79) 16 (55.17) 29
Cefotaxime CTX 30 0 (0) 0 (0) 29 (100) 29
Cefoxitin CX 30 0 (0) 0 (0) 29 (100) 29
Ceftazidime CAZ 30 1 (3.44) 0 (0) 28 (96.55) 29
Ceftriaxone CTR 30 0 (0) 0 (0) 29 (100) 29
Chloramphenicol C 30 9 (31.03) 2 (6.89) 18 (62.06) 29
Ciprofloxacin CIP 5 1 (3.44) 0 (0) 28 (96.55) 29
Colistin CL 10 28 (96.55) 0 (0) 1 (3.44) 29
Cotrimoxazole COT 1.25/23.75 3 (10.34) 0 (0) 26 (89.65) 29
Gentamycin GEN 10 3 (10.34) 1 (3.44) 25 (86.20) 29
Imipenem IPM 10 9 (31.03) 1 (3.44) 19 (65.51) 29
Meropenem MRP 10 8 (27.58) 2 (6.89) 19 (65.51) 29
Netromycin NET 30 6 (20.68) 0 (0) 23 (79.31) 29
Ofloxacin OF 5 2 (6.89) 3 (10.34 24 (82.75) 29
Piperacillin/Tazobactam PIT 100/10 2 (6.89) 1 (3.44) 26 (89.65) 29
Polymyxin-B PB 300 units 29 (100) 0 (0) 0 (0) 29
Ticarcillin TI 75 0 (0) 0 (0) 29 (100) 29
Tobramycin TOB 10 5 (17.24) 0 (0) 24 (82.75) 29
N: Number of isolates
Table 4: Ranking of antibiotic resistance for Acinetobacter sp. isolates against commonly used antibiotics
Serial No. Rank Antibiotic used Resistant isolates
Number %
1 1 Ampicillin 29 100  Most Resistant
2 1 Cefoperazone 29 100
3 1 Cefotaxime 29 100
4 1 Cefoxitin 29 100
5 1 Ceftriaxone 29 100
6 1 Ticarcillin 29 100
7 2 Ceftazidime 28 96.55
8 2 Ciprofloxacin 28 96.55
9 3 Cotrimoxazole 26 89.65
10 3 Piperacillin/Tazobactam 26 89.65
11 4 Amikacin 25 86.20
12 4 Gentamycin 25 86.20
13 5 Ofloxacin 24 82.75
14 5 Tobramycin 24 82.75
15 6 Netromycin 23 79.31
16 7 Imipenem 19 65.51
17 7 Meropenem 19 65.51
18 8 Chloramphenicol 18 62.06
19 9 Cefoperazone/Sulbactam 16 55.17
20 10 Colistin 1 3.44
21 11 Polymyxin-B 0 0 Most Sensitive
The commonly encountered hospital isolates of Acinetobacter sp. 
include A. baumannii, A. iwoffii and A. hemolyticus. The risk factors 
attributed to the life-threatening Acinetobacter sp. related nosocomial 
infections seek their grounds on account of increased invasive or 
surgical procedures, excessive use of broad-spectrum antimicrobials 
and prolonged stay in the hospitals [19]. The treatment of Acinetobacter 
sp. infections holds a backlog in lieu of their property to rapidly develop 
resistance to antimicrobials [23]. It is also reported that Acinetobacter 
sp. can inherit genes from Pseudomonas sp. and Salmonella sp. thorough 
horizontal gene transfer and this property of innate resistance is 
exclusively plasmid-borne [14].
In this study, the pathogen under question constituted a way high of 
42.02%, among all the nosocomial bacterial ICU isolates. Similarly, 
higher rates of prevalence with respect to the Indian scenario were 
also observed by other researchers [24,25]. The respiratory problems 
caused due to MDR Acinetobacter sp. are the most commonly associated 
problems with the ICU patients [14]. According to the findings of this 
study, Acinetobacter sp. was also mostly isolated from respiratory 
tract samples followed by the specimens falling under pus category, 
succeeded by UTIs, surgical site infections, and finally the bloodstream 
infections (BSIs). The higher incidence of isolation of Acinetobacter 
sp. from respiratory tract samples has also been previously well 
documented by various researchers worldwide [26-28]. Among the 
ICU infections as prevailing in Europe, a share of about 10% have been 
acknowledged to Acinetobacter sp. [29].
The colonization of Acinetobacter sp. in indwelling patients, employees 
of health-care facility and healthy subjects occur frequently. The 
upcoming challenge lies in the thorough and effective management of 
Acinetobacter sp. infections as it shows an innate predilection for broad-
spectrum antimicrobial resistance along with its emerging ability to 
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rapidly develop novel patterns of drug resistance. Antimicrobial agents 
typically active against Acinetobacter sp. include the carbapenems 
(IPM and MRP), AK, sulbactum, CL, Rifampin, and tetracyclines but 
recent studies report its resistance against β-lactam antibiotics, broad-
spectrum cephalosporins, aminoglycosides and fluoroquinolones too, 
which are otherwise considered as the ground line or basic stepwise 
treatment so as to be followed according to the medical therapeutics 
with respect to the severity of corresponding infection [24].
During this study, more than 95% of the Acinetobacter sp. isolates were 
found to be MDR isolates while majority of them were resistant to 
commonly used antibiotics such as CAZ, CIP, AK, GEN, OF, TOB, and NET 
suggesting that MDR isolates are widely increasing in this geographical 
region too, perhaps due to the prolonged and indiscriminate use of 
such antibiotics in the health-care setups. A study done in Pune, India, 
showed that about 48% to 68.6% of A. baumannii isolates were MDR 
[30].
Till recently carbapenems (MRP and IPM) were considered as the gold 
standard for treating Acinetobacter sp. infections, but unfortunately, 
carbapenem resistance toward Acinetobacter sp. is becoming common 
globally [31,32]. Resistance to carbapenems (XDR isolates) has also 
been widely reported [33,34]. In general, Acinetobacter sp. shows a 
greater resistance to MRP than IPM [35,36]. A study conducted on A. 
baumannii isolates in US quoted IPM resistance to be at the scale of 
23.1% [37]. In this study also, the resistance pattern as exhibited for 
carbapenems along with PIT exceeded the mid-way dilemma, i.e. being 
greater than 50%, thereby indicating that the Acinetobacter sp. isolates 
under question were definitely of the order of XDR too.
Pan drug-resistant A. baumannii isolates, i.e., isolates resistant to 
all antimicrobial agents in vitro, have also been reported from some 
areas of the world as Asia and the Middle-east [38]. The prospective 
of combination therapy could be given a thought, but it is still tagged 
as controversial due to the non-availability of any proven improvement 
data in the context of subjective mortality along with a subsequent 
high-grade toxicity [38].
In this present face of broad-spectrum antimicrobial resistance, CL aka 
polymyxin E typically retains its activity against Acinetobacter sp., but 
it is also duly reported to be neurotoxic, nephrotoxic, and ototoxic in 
the long run thereby limiting its routine use, though the toxicity has 
been found to be correspondingly similar to other antimicrobials 
used frequently in ICUs [38]. In the present study, the resistance to CL 
was seen in the order of 3.44% leaving PB as the last resort against 
which this Acinetobacter sp. was sensitized. A recent study in an ICU 
of a tertiary hospital, Haryana, India, also showed upcoming resistance 
patterns against CL in the scale of 1.2% [28]. A study done in the 
Western Pacific region showed that 3.3% of A. baumannii isolates were 
resistant toward CL [39].
The higher percentage of antimicrobial resistance toward carbapenems 
as demonstrated by the isolated Acinetobacter sp. in this study 
encompassing Ludhiana, Punjab, India, leaves us with polymyxins as 
the only last standing post in this crucial war against MDR and XDR 
Acinetobacter sp. isolates. Thus, the need of the hour is to seriously 
undertake stringent measures that should have a positive impact 
against such obstinate MDR and XDR nosocomial isolates, thereby 
decreasing and restricting the use of antimicrobials to only those 
situations where they are actually called for and that too in a proper 
dose and for a proper duration of time.
CONCLUSION
During this study, a total of 298 clinical samples were collected 
from a various set of ICU patients and subjected to isolation and 
characterization for various nosocomial bacterial isolates. Among 
the total positive culture samples so obtained, 42% were allocated to 
Acinetobacter sp. while most of the HAIs ascribed to Acinetobacter sp. 
were related to the respiratory tract (63.15%). The drug resistance 
patterns showed that >95% of Acinetobacter sp. were MDR, whereas 
more than 50% of Acinetobacter sp. isolates showed XDR. The last ray 
of hope for such dreaded Acinetobacter sp. hospital-based etiology 
at present is only left to CL and PB. Therefore, in the perspective of 
this study, it could be concluded that emergence of high-grade MDR 
Acinetobacter sp. within the ICUs of Ludhiana, Punjab, India, is the 
newest problem on the board. The ongoing MDR nature of this pathogen 
to multiple drugs or even to the last line antibiotics is a severe looming 
threat with respect to the already immunity weaned ICU inhabitants. 
The probable escape lies in the thorough periodic monitoring of the 
health-care setups so as to plan out effective infection control strategies 
and chalking out new treatment options for genuinely controlling 
such stubborn hospital-based Acinetobacter sp. pathologies within the 
overall domain of Punjab, India.
ACKNOWLEDGMENT
The authors wish to thank the management of Christian Medical 
College and Hospital, Ludhiana, Punjab, India, and Lovely Professional 
University, Phagwara, Punjab, India, for extending their kind support in 
providing all necessary facilities to carry out this study.
REFERENCES
1. Kauffman C. Acinetobacter species. Infect Dis Advis 2017;2017:609604. 
Available from: https://www.infectiousdiseaseadvisor.com/infectious-
diseases/Acinetobacter species/article/609604.
2. Ochei J, Kolhatkar A. Medical Laboratory Science, Theory and 
Practice. 1st ed. New Delhi: Tata McGraw-Hill Publishing Company 
Limited; 2000. p. 712.
3. Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, 
biology and pathogenesis of Acinetobacter spp.: An overview. Microbe 
Environ 2011;26:101-12.
4. Gautam V, Singhal L, Ray P. Burkholoderia cepacia complex: Beyond 
Pseudomonas and Acinetobacter. Indian J Med Microbiol 2011;29:4-12.
5. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, 
et al. Acinetobacter baumannii: An emerging multidrug-resistant 
pathogen in critical care. Crit Care Nurse 2008;28:15-25.
6. Cisneros JM, Rodríguez-Baño J, Fernández-Cuenca F, Ribera A, Vila J, 
Pascual A, et al. Risk-factors for the acquisition of imipenem-resistant 
Acinetobacter baumannii in Spain: A nationwide study. Clin Microbiol 
Infect 2005;11:874-9.
7. Falagas ME, Kopterides P. Risk factors for the isolation of multidrug-
resistant Acinetobacter baumannii and Pseudomonas aeruginosa: 
A systematic review of the literature. J Hosp Infect 2006;64:7-15.
8. Medina J, Formento C, Pontet J, Curbelo A, Bazet C, Gerez J, et al. 
Prospective study of risk factors for ventilator-associated pneumonia 
caused by Acinetobacter species. J Crit Care 2007;22:18-27.
9. Katsaragakis S, Markogiannakis H, Toutouzas KG, Drimousis P, 
Larentzakis A, Theodoraki EM, et al. Acinetobacter baumannii 
infections in a surgical intensive care unit: Predictors of multidrug 
resistance. World J Surg 2008;32:1194-202.
10. Lemuel LD, Marshall DR, Pratap S, Hulette RB. Multidrug resistant 
Acinetobacter baumannii: A descriptive study in a city hospital. BMC 
Infect Dis 2010;10:196.
11. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to 
Acinetobacter baumannii. Clinical features, epidemiology, and 
predictors of mortality. Med (Baltimore) 1995;74:340-9.
12. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact 
of imipenem resistance on mortality in patients with Acinetobacter 
bacteraemia. J Antimicrob Chemother 2007;59:525-30.
13. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, 
Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality 
rate and length of hospitalization. Emerg Infect Dis 2007;13:97-103.
14. Nandi D, Arjuna A. Acinetobacter main cause of hospital acquired 
infections: A review. Asian J Pharm Clin Res 2017;10:53-6.
15. CDC (Centers for Disease Control and Prevention). Collection, 
Handling, and Shipment of Microbiological Specimens. Available 
from: https://www.stacks.cdc.gov/view/cdc/44272.
16. Collee JG, Frase AG, Marmion BP, Simmons A. Laboratory strategy 
in the diagnosis of infective syndromes. In: Mackie and McCartney 
Practical Medical Microbiology. 14th ed. India: Elsevier Health 
Sciences; 1996. p. 84-90.
17. Betty AF, Daniel FS, Alice SW. Bailey and Scott’s Diagnostic 
Microbiology. 12th ed. Philadelphia: Elsevier; 2007.
93
 Kaur et al.
Asian J Pharm Clin Res, Vol 11, Special issue 2, 2018, 88-93
18. CLSI (Clinical and Laboratory Standards Institute). Performance 
Standards for Antimicrobial Susceptibility Testing. 27th ed. Wayne, 
PA: Clinical and Laboratory Standards Institute; 2017. Available from: 
http://www.facm.ucl.ac.be/intranet/CLSI/CLSI-2017-M100-S27.pdf.
19. Vaja K, Kavathia GU, Goswami YS, Chouhan S. A prevalence study 
of Acinetobacter species and their sensitivity pattern in a tertiary care 
hospital Rajkot city of Gujarat (India): A hospital based study. IOSR J 
Pharm Biol Sci 2016;15:54-8.
20. Colle JG, Fraser AG, Marmion BP, Simmons A. Practical Medical 
Microbiology. 14th ed. New York: Churchill Livingstone; 1996. 
p. 294-6.
21. Koneman EW, Allen SD, Jande WM, Schreckenberger PC, Winn 
WC Jr. Colour Atlas and Text Book Diagnostic Microbiology. 5th ed. 
Baltimore: Lippincott; 1997. p. 286-7.
22. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant 
Acinetobacter baumannii: A descriptive study in a city hospital. BMC 
Infect Dis 2010;10:196.
23. Bernards AT, Harinck HI, Dijkshoom L, Van der Reijden TJ, Van 
den Broek PJ. Persistant Acinetobacter baumannii? Look inside your 
medical equipment. Infect Control Hosp Epidemiol 2004;25:1002-4.
24. Bhattacharyya S, Bhattacharyya I, Rit K, Mukhopadhyay PK, Dey JB, 
Ganguly U, et al. Antibiogram of Acinetobacter spp. isolated from 
various clinical specimens in a tertiary care hospital in West Bengal, 
India. Biomed Res 2013;24:43-6.
25. Sudhaharan S, Lakshmi V, Padmaja K. Prevalence of multidrug 
resistant Acinetobacter baumannii in clinical samples in a tertiary care 
hospital. Int J Infect Control 2015;11:1-5.
26. Siau H, Yuen, KY, Wong SSY. The epidemiology of Acinetobacter 
infections in Hong Kong. J Med Microbiol 1996;44:340-7.
27. Asensio A, Canton R, Vague J, Calbo-Torrecillas F, Herruzo R, 
Arribas JL, et al. Prevalence of infection by Carbapenem resistant A. 
baumanni in Spain (1999-2005). Enferm Infect Microbiol Clin 
2008;26:199-204.
28. Jaggi N, Sissodia P, Sharma L. Acinetobacter baumannii isolates in a 
tertiary care hospital: Antimicrobial resistance and clinical significance. 
J Microbiol Infect Dis 2012;2:57-63.
29. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence 
of a successful pathogen. Clin Microbiol Rev 2008;21:538-82.
30. Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, 
Niphadkar KB. Clinical and demographic features of infection caused 
by Acinetobacter species. Indian J Med Sci 2006;60:351-60.
31. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallobetalactamases: 
The quiet before the storm? Clin Microbiol Rev 2005;18:306-25.
32. Towner KJ. Acinetobacter: An old friend, but a new enemy. J Hosp 
Infect 2009;73:355-63.
33. Fournier PE, Richet H. The epidemiology and control of Acinetobacter 
baumannii in healthcare facilities. Clin Infect Dis 2006;42:692-9.
34. Hu Q, Hu Z, Li J, Tian B, Xu H, Li J. Detection of OXA-type 
carbapenemases and integrons among carbapenem resistant 
Acinetobactor baumannii in a teaching hospital in China. J Basic 
Microbiol 2011;51:467-72.
35. Gupta E, Mohanty S, Sood S, Dhavan B, Das BK, Kapil A. Emerging 
resistance to carbapenems in a tertiary care hospital in North India. 
Indian J Med Res 2006;124:95-8.
36. Gaur A, Gang A, Prakash P, Anupurba S, Mohapatra TM. Observations 
on carbapenem resistance by minimum inhibitory concentration in 
nosocomial isolates of Acinetobacter species. J Health Popul Nutr 
2008;26:183-8.
37. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, 
et al. Epidemiology and impact of imipenem resistance in Acinetobacter 
baumannii. Infect C Hosp Epidemiol 2009;30:1186-92.
38. Clinical Laboratory Standards Institute (CLSI). Performance Standards 
for Antimicrobial Susceptibility Testing. 16th Informational Suppl. 
Wayne PA. Clinical Laboratory Standards Institute (CLSI); 2006.
39. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, et al. Colistin 
heteroresistance in multidrug-resistant Acinetobacter baumannii 
clinical isolates from the western pacific region in the SENTRY 
antimicrobial surveillance programme. J Infect 2009;58:138-44. 
